LoginRegister

    Cipla gets USFDA EIR for Invagen manufacturing facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  
    Cipla gets USFDA EIR for Invagen manufacturing facility

    New Delhi: Homegrown pharma major Cipla on Tuesday said it has received a report from the US health regulator indicating closure of the inspection at its US Invagen manufacturing facility.

    "Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019, to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.

    Read also: Japanese financial group MUFG sells 2.10pc shares in Cipla
    The shares of Cipla were trading at Rs 463.20 a piece on BSE in morning trade, down 0.31 per cent from the previous close.
    Read also: Cipla gets USFDA observations for its Goa facility

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      sidekick